Control

Every year, lives are lost because of the spread of infections in hospitals. Health care workers can take steps to prevent the spread of infectious diseases. These steps are part of infection control.

Proper hand washing is the most effective way to prevent the spread of infections in hospitals. If you are a patient, don't be afraid to remind friends, family and health care providers to wash their hands before getting close to you.

Other steps health care workers can take include:

Covering coughs and sneezes
Staying up to date with vaccinations
Using gloves, masks and protective clothing
Making tissues and hand cleaners available
Following hospital guidelines when dealing with blood or contaminated items

Control FDA Approved Drugs

ACTOPLUS MET XR [Metformin Hydrochloride^{C₄H₁₁N₅ClH} : Pioglitazone Hydrochloride^{C₁₉H₂₀N₂O₃SClH}]

1gm : eq 15mg base (oral tablet, extended release)

1gm : eq 30mg base (oral tablet, extended release)

Takeda Pharms Usa^{May 12, 2009}

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with pioglitazone and metformin or who have inadequate glycemic control on pioglitazone or metformin alone.
Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a pioglitazone and metformin.
To reduce gastrointestinal side effects administer with a meal; as starting dose administer once daily with evening meal.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ACULAR LS [Ketorolac Tromethamine^{C₁₅H₁₃NO₃C₄H₁₁NO₃}]

0.4% (ophthalmic solution/drops)

Allergan^{May 30, 2003}

A method of controlling postoperative ocular pain and burning/stinging in a patient.
A method of treating ocular pain and/or enhancing ocular comfort.
A method of treating ocular pain.
A method of treating or preventing ocular pain and burning.
A method of treating or preventing ocular pain and burning/stinging following corneal surgery.
A method of treating or preventing ocular pain in a patient.
A method of treating or reducing ocular pain and burning/stinging.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ADLYXIN [Lixisenatide]

0.15mg/3ml (0.05mg/ml) (subcutaneous solution)

0.3mg/3ml (0.1mg/ml) (subcutaneous solution)

Sanofi-aventis Us^{Jul 27, 2016}

Combination treatment with a glitazone for improvement of glycemic control in type 2 diabetes mellitus patients.
Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector.

efficacy
4.0 (1)

side effects
0.0 (0)

danger
0.0 (0)

AFREZZA [Insulin Recombinant Human]

12 units/inh (inhalation powder)

4 units/inh (inhalation powder)

8 units/inh (inhalation powder)

Mannkind^{Apr 17, 2015}

Administration of a composition comprising insulin complexed with a diketopiperazine..
Administration of a composition comprising insulin complexed with microparticles of a diketopiperazine..
Administration of fdkp microparticles comprising insulin..
Method of aerosolizing/deagglomerating an insulin dry powder for use in treating diabetes mellitus via oral inhalation using an inhaler with a cartridge containing the insulin dry powder..
Method of controlling glycemia in diabetics by administering an initial dose of insulin-fdkp with a meal; determining blood glucose level 1-2 hrs after and administering a supplemental dose of insulin-fdkp if postprandial glucose level is >140 mg/dl.
Method of delivering to a patient with diabetes mellitus in a single inhalation, greater than 75% of a dry powder dose comprising insulin and fumaryl diketopiperazine using a high resistance to flow dry powder inhaler..
Pulmonary administration of a compisition comprising insulin bound to a diketopiperazine..
Pulmonary administration of a composition comprising insulin bound to a complexing agent..
Pulmonary administration of an insulin composition comprising fdkp at the beginning of a meal to a patient also being treated with a long-acting insulin..
Treatment of a patient having diabetes mellitus with a prandial rapid acting insulin..
Treatment of diabetes mellitus with an inhaled insulin to improve glycemic control using a dry powder inhalation system comprising an inhaler, a cartridge and a dry powder medicament comprising insulin in a single inhalation.
Treatment of patient having diabetes mellitus via oral inhalation of fdkp microparticles comprising insulin.
Use of an inhaler to administer dry powder medicament.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

APIDRA [Insulin Glulisine Recombinant]

1000 units/10ml (100 units/ml) (iv (infusion), subcutaneous injectable)

300 units/3ml (100 units/ml) (iv (infusion), subcutaneous injectable)

Sanofi Aventis Us^{Apr 16, 2004}

Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
Method of treating a patient suffering from diabetes mellitus.

efficacy
1.0 (1)

side effects
0.0 (0)

danger
0.0 (0)

APIDRA SOLOSTAR [Insulin Glulisine Recombinant]

300 units/3ml (subcutaneous injectable)

Sanofi Aventis Us^{Feb 24, 2009}

Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
Method of treating a patient suffering from diabetes mellitus.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

AURYXIA [Ferric Citrate]

eq 210mg iron (oral tablet)

Keryx Biopharms^{Sep 5, 2014}

Control of serum phosphorous levels.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

BELVIQ [Lorcaserin Hydrochloride]

10mg (oral tablet)

Eisai Inc^{Jun 27, 2012}

Method for chronic weight management by decreasing food intake in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by decreasing food intake.
Method for chronic weight management by inducing satiety in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by inducing satiety.
Method for chronic weight management by treating obesity in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by treating obesity.
Method for chronic weight management.
Method for chronic wieght management by controlling weight gain.
Use of belviq (lorcaserin hydrochloride) for chronic weight management by decreasing food intake in patients on a reduced-calorie diet and who have achieved greater than or equal to 5% weight loss by week 12 of treatment.
Use of belviq (lorcaserin hydrochloride) for chronic weight management by inducing satiety in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.
Use of belviq (lorcaserin hydrochloride) for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.
Use of belviq (lorcaserin hydrochloride) for chronic weight management in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

BELVIQ XR [Lorcaserin Hydrochloride]

20mg (oral tablet, extended release)

Eisai Inc^{Jul 15, 2016}

Method for chronic weight management by decreasing food intake in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by decreasing food intake.
Method for chronic weight management by inducing satiety in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by inducing satiety.
Method for chronic weight management by treating obesity in an individual who does not have severe renal impairment or esrd.
Method for chronic weight management by treating obesity.
Method for chronic weight management.
Method for chronic wieght management by controlling weight gain.
Use of lorcaserin hydrochloride for chronic weight management by decreasing food intake in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.
Use of lorcaserin hydrochloride for chronic weight management by inducing satiety in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.
Use of lorcaserin hydrochloride for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.
Use of lorcaserin hydrochloride for chronic weight management in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of treatment.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

BYDUREON [Exenatide Synthetic]

2mg/vial (subcutaneous for suspension, extended release)

Astrazeneca Ab^{Jan 27, 2012}

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
Reductions in body weight are observed with exenatide.
Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
Treatment of type 2 diabetes.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

BYDUREON PEN [Exenatide Synthetic]

2mg (subcutaneous for suspension, extended release)

Astrazeneca Ab^{Feb 28, 2014}

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
Reductions in body weight are observed with exenatide.
Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
Treatment of type 2 diabetes.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

CETROTIDE [Cetrorelix^{C₇₀H₉₂ClN₁₇O₁₄}]

eq 0.25mg base/ml (injection injectable)

Emd Serono Inc^{Aug 11, 2000}

Prevention of premature lh surges in women undergoing controlled ovarian stimulation.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

COMBIGAN [Brimonidine Tartrate^{C₁₁H₁₀BrN₅C₄H₆O₆} : Timolol Maleate^{C₁₃H₂₄N₄O₃SC₄H₄O₄}]

0.2% : eq 0.5% base (ophthalmic solution/drops)

Allergan^{Oct 30, 2007}

Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of combigan in the affected eye twice daily.
Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop.
Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension.
Reduction of elevated intraocular pressure.
Reduction of intraocular pressure in patients with elevated intraocular pressure or glaucoma.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

CYCLOSET [Bromocriptine Mesylate^{C₃₂H₄₀BrN₅O₅CH₄O₃S}]

eq 0.8mg base (oral tablet)

Veroscience^{May 5, 2009}

Administration once daily within two hours after waking in the morning for improvement of glycemic control in a type 2 diabetes patient.
Improvement of glycemic control in individuals with type 2 diabetes.
Improvements of glycemic control in individuals with type 2 diabetes who have one or more specified cardiovascular risk factors.
Treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined therapeutic effect is greater than the additive effect of administering each agent alone.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

DUETACT [Glimepiride^{C₂₄H₃₄N₄O₅S} : Pioglitazone Hydrochloride^{C₁₉H₂₀N₂O₃SClH}]

2mg : 30mg (oral tablet)

4mg : 30mg (oral tablet)

Takeda Pharms Usa^{Jul 28, 2006}

As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

FARXIGA [Dapagliflozin Propanediol^{C₂₁H₂₅ClO₆C₃H₈O₂H₂O}]

eq 10mg base (oral tablet)

eq 5mg base (oral tablet)

Astrazeneca Ab^{Jan 8, 2014}

Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone.
Treatment of type 2 diabetes mellitus.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

GANIRELIX ACETATE [Ganirelix Acetate^{C₈₀H₁₁₃ClN₁₈O₁₃2C₂H₄O₂}]

eq 250mcg base/0.5ml (injection injectable)

Organon Usa Inc^{Jul 29, 1999}

Inhibition of premature lh surges in women undergoing controlled ovarian hyperstimulation with fsh.

efficacy
0.0 (0)

side effects
0.0 (0)

GLUCOTROL XL [Glipizide^{C₂₁H₂₇N₅O₄S}]

10mg (oral tablet, extended release)

2.5mg (oral tablet, extended release)

Pfizer^{Apr 26, 1994}

Method of treating hyperglycemia to improve glycemic control in a patient by oral admin of once a day osmotic dosage form of glipizide with polyethylene oxide, hydroxypropylmethylcellulose, cellulose acetate, and sodium chloride.

JANUMET [Metformin Hydrochloride^{C₄H₁₁N₅ClH} : Sitagliptin Phosphate^{C₁₆H₁₅F₆N₅OH₂OH₃O₄P}]

1gm : eq 50mg base (oral tablet)

500mg : eq 50mg base (oral tablet)

Merck Sharp Dohme^{Mar 30, 2007}

Improvement of glycemic control in adults with type 2 diabetes mellitus.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.

JANUMET XR [Metformin Hydrochloride^{C₄H₁₁N₅ClH} : Sitagliptin Phosphate^{C₁₆H₁₅F₆N₅OH₂OH₃O₄P}]

1gm : eq 100mg base (oral tablet, extended release)

1gm : eq 50mg base (oral tablet, extended release)

500mg : eq 50mg base (oral tablet, extended release)

Merck Sharp Dohme^{Feb 2, 2012}

Improvement of glycemic control in adults with type 2 diabetes mellitus.
Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate.

JANUVIA [Sitagliptin Phosphate^{C₁₆H₁₅F₆N₅OH₂OH₃O₄P}]

eq 100mg base (oral tablet)

eq 25mg base (oral tablet)

eq 50mg base (oral tablet)

Merck Sharp Dohme^{Oct 16, 2006}

Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin and/or a ppar-gamma agonist and/or sulfonylurea and/or insulin.
Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin..
Improvement of glycemic control in adults with type 2 diabetes mellitus.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidaste-iv inhibitor.

JENTADUETO XR [Linagliptin^{C₂₅H₂₈N₈O₂} : Metformin Hydrochloride^{C₄H₁₁N₅ClH}]

2.5mg : 1gm (oral tablet, extended release)

Boehringer Ingelheim^{May 27, 2016}

Method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin.
Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin.
Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.
Method of treating type 2 diabetes.

KOMBIGLYZE XR [Metformin Hydrochloride^{C₄H₁₁N₅ClH} : Saxagliptin Hydrochloride^{C₁₈H₂₅N₃O₂ClH}]

1gm : eq 2.5mg base (oral tablet, extended release)

1gm : eq 5mg base (oral tablet, extended release)

500mg : eq 5mg base (oral tablet, extended release)

Astrazeneca Ab^{Nov 5, 2010}

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
Method for treating type ii diabetes mellitus by administering saxagliptin in combination with metformin.

LANTUS [Insulin Glargine Recombinant]

100 units/ml (injection injectable)

Sanofi Aventis Us^{Apr 20, 2000}

Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.

LANTUS SOLOSTAR [Insulin Glargine Recombinant]

300 units/3ml (100 units/ml) (injection injectable)

Sanofi Aventis Us^{Apr 27, 2007}

Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.

OPANA ER [Oxymorphone Hydrochloride^{C₁₇H₁₉NO₄ClH}]

10mg (oral tablet, extended release)

15mg (oral tablet, extended release)

20mg (oral tablet, extended release)

30mg (oral tablet, extended release)

40mg (oral tablet, extended release)

7.5mg (oral tablet, extended release)

Endo Pharms^{Dec 9, 2011}

Method of administration of controlled release oxymorphone.

QTERN [Dapagliflozin Propanediol^{C₂₁H₂₅ClO₆C₃H₈O₂H₂O} : Saxagliptin Hydrochloride^{C₁₈H₂₅N₃O₂ClH}]

eq 10mg base : eq 5mg base (oral tablet)

Astrazeneca Ab^{Feb 27, 2017}

Method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin.
Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin.

RAYALDEE [Calcifediol^{C₂₇H₄₄O₂H₂O}]

0.03mg (oral capsule, extended release)

Opko Ireland Global^{Jun 17, 2016}

Administration of 25-hydroxyvitamin d3 by controlled release.
Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d.
Use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease.
Use of extended release oral 25-hydroxyvitamin d3 in treating secondary hyperparathyroidism in adult patients having chronic kidney disease stage 3 or stage 4.
Use of sustained release 25-hydroxyvitamin d in treating patients having 25-hydroxyvitamin d insufficiency or deficiency.

SOLIQUA 100/33 [Insulin Glargine^{C₂₆₇H₄₀₄N₇₂O₇₈S₆} : Lixisenatide]

300 units/3ml : 99mcg/3ml (100 units/ml : 33mcg/ml) (subcutaneous solution)

Sanofi-aventis Us^{Nov 21, 2016}

Improvement in glycemic control in adults with type 2 diabetes mellitus inadequately controlled by basal insulin or lixisenatide by use of a pen injector with a threaded drive sleeve.

TOUJEO SOLOSTAR [Insulin Glargine Recombinant]

300 units/ml (300 units/ml) (subcutaneous solution)

Sanofi Us Services^{Feb 25, 2015}

Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
Improvement in glycemic control in diabetes mellitus patients.

VARITHENA [Polidocanol^{C₁₂H₂₆O(C₂H₄O)n}]

180mg/18ml (10mg/ml) (intravenous solution)

Provensis^{Nov 25, 2013}

A method of generating an injectable foam of controlled density and bubble size.
A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities.
A method of using a sclerosing agent for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous (gsv) system above and below the knee.

VELPHORO [Sucroferric Oxyhydroxide]

500mg (oral tablet, chewable)

Vifor Fresenius^{Nov 27, 2013}

Control of phosphorous levels in patients.

VICTOZA [Liraglutide Recombinant]

18mg/3ml (6mg/ml) (subcutaneous solution)

Novo Nordisk Inc^{Jan 25, 2010}

A method for improving glycemic control in adults with type 2 diabetes mellitus.

XERMELO [Telotristat Etiprate^{C₂₇H₂₆ClF₃N₆O₃C₉H₉NO₃}]

eq 250mg base (oral tablet)

Lexicon Pharms Inc^{Feb 28, 2017}

The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy.

XIGDUO XR [Dapagliflozin Propanediol^{C₂₁H₂₅ClO₆C₃H₈O₂H₂O} : Metformin Hydrochloride^{C₄H₁₁N₅ClH}]

eq 10mg base : 1gm (oral tablet, extended release)

eq 10mg base : 500mg (oral tablet, extended release)

eq 5mg base : 1gm (oral tablet, extended release)

eq 5mg base : 500mg (oral tablet, extended release)

Astrazeneca Ab^{Oct 29, 2014}

Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone.
Treatment of type 2 diabetes mellitus.

XYREM [Sodium Oxybate^{C₄H₇O₃Na}]

500mg/ml (oral solution)

Jazz Pharms^{Jul 17, 2002}

A method of treating a patient with a prescription drug using an exclusive computer database in a computer system for distribution.
A method to control abuse of a sensitive drug by controlling with a computer processor the distribution of the sensitive drug via an exclusivity central pharmacy that maintains a central database.
Method of treating a patient with a prescription drug using a computer database in a computer system for distribution.
Method of treating cataplexy in patients with narcolepsy.
Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered..
Method of treating excessive daytime sleepiness in patients with narcolepsy.

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.

WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for reference only. Many of these treatments may be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field. The owner of this website will not be held liable for any injuries and deaths cause by following any home remedies. We have no control of what is posted.

Home Remedies for Control

PREGNANCY [contraception]
Emergency contraception is to only be used after unprotected sex, not for regular birth control. Emergency contraception that contains the same hormone used in many birth control pills - just at a higher dose. Helps prevent pregnancy. It should not be used as regular birth control because it's not as effective.
Mechanism - hormoneShizs | July 15th, 2018

TOE NAIL FUNGUS [Onychomycosis]
The only real "cure" is taking Lamisil (terbinafine hydrochloride) tablets prescribed by a doctor. The longer durations (at weaker doses) allow the nail to grow out. However, this medication can damage your liver. Once the initial infection is under control, brush Vicks Vaporub (or generic) under and around the nail with a toothbrush twice a day to reduce the chance of coming back.Sleslie | July 26th, 2021

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

Control

Control FDA Approved Drugs

Home Remedies for Control